Covid-19 Testing Leader Andon Health Co.Ltd(002432) strong daily limit achieved two boards, with a daily turnover of 4.55 billion yuan and a closing price of 81.92 yuan, approaching the historical highest price of 88.88 yuan . .
What are the funds behind and Andon Health Co.Ltd(002432) the data of the one-day list released after hours showed that the funds of the dragon and tiger list net sold 60.63 million yuan . China stock market news securities, known as ” retail base “, bought five seats in Lhasa, with a net purchase of 13.69 million yuan institution specific ranked among the four seats sold, with a net sales of 57.06 million yuan. According to the data of Andon Health Co.Ltd(002432) yesterday’s Dragon and tiger list, institution specific occupied one seat and a net purchase of 159 million yuan.
Andon Health Co.Ltd(002432) yesterday’s “burst” performance forecast raised questions from some market participants. The company released share price change announcement tonight said that there was no need to correct and supplement the information disclosed in the early stage, and did not modify the performance forecast for the first quarter of 2022 .
covid-19 antigen detection kit has made an important contribution to proud transcripts ihealth US subsidiary sells ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signs major contracts and orders with customers.
At present, Andon Health Co.Ltd(002432) covid-19 self-test kit has not yet entered the Chinese market. If the company’s products are launched in China, whether they will create more performance myths has aroused many investors’ speculation. According to media reports this afternoon, company said it would respond according to market conditions .
The performance forecast shows that Andon Health Co.Ltd(002432) expects the net profit in the first quarter of 2022 to be 14-16 billion yuan, with a year-on-year increase of 3670743% – 4196563%. “cash capacity” is close to Kweichow Moutai Co.Ltd(600519) , and Maotai’s net profit in the first quarter is expected to be 16.6 billion yuan.
Andon Health Co.Ltd(002432) in the past ten years (20122021), the total profit was 940 million yuan, which is equivalent to that Andon Health Co.Ltd(002432) made about 15 times more money in one quarter than it did in the past ten years. In other words, Andon Health Co.Ltd(002432) made money in one quarter, which used to take 150 years , which can be called a “money printer”.
Public information shows that Andon Health Co.Ltd(002432) focuses on R & D, production and sales of home medical devices, as well as cloud platform systems and services. The main products are platforms for patients with diabetes, and the main market is abroad. The self-test version of covid-19 antigen detection reagent developed by the company has successively obtained EU CE, German bfarm, Austrian basg, Czech MZCR self-test white list and other certifications, and can be sold in the above-mentioned countries.
Analysts pointed out that it can be predicted that will have more and more brands of household testing kits approved by FDA , and the competition of kits in the world will become more and more fierce.
He bin, a special researcher of the public policy research center of the Chinese Academy of Social Sciences, believes that U.S. government policies are likely to change, and the procurement cost of hundreds of millions of copies is unsustainable . At present, the hot kit market is more “political action” and ” short-term behavior “.
For the American people, due to the surge of covid-19 cases, household kits have been in short supply for a long time . At present, the policy of the U.S. government is that each person can reimburse the cost of kit 8 times a month from the insurance company. However, he bin also added that once the U.S. government does not reimburse, the product sales of household kits will be greatly reduced .
It is worth noting that the seller’s organization has little interest in Andon Health Co.Ltd(002432) .
